Elicio Therapeutics
ELTX
43 hedge funds and large institutions have $5.9M invested in Elicio Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 16 reducing their positions, and 16 closing their positions.
0.45% less ownership
Funds ownership: 2.18% → 1.73% (-0.45%)
9% less funds holding
Funds holding: 47 → 43 (-4)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
57% less capital invested
Capital invested by funds: $13.8M → $5.9M (-$7.95M)
69% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$293K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$217K |
| 3 |
E
Ergoteles
New York
|
+$143K |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$121K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.52M |
| 2 |
State Street
Boston,
Massachusetts
|
-$303K |
| 3 |
JP Morgan Chase
New York
|
-$300K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$254K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$244K |
ELTX Hedge Fund Activity: Q2 2022 in Review
43 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q2 2022, worth a combined $5.9M — down 57% from $13.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ELTX and 13 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $293K. The largest seller was BlackRock, cutting an estimated $1.52M.
- 43 institutional investors held Elicio Therapeutics (ELTX) as of Q2 2022, down from 47 in Q1 2022.
- Funds reported $5.9M of Elicio Therapeutics stock for Q2 2022, down 57% quarter-over-quarter.
- 13 funds opened new Elicio Therapeutics positions in Q2 2022 and 16 closed out, a net change of -3 holders.
- The largest Elicio Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $293K added.
- The largest Elicio Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.52M sold.
Based on aggregated 13F filings for Q2 2022.